Why Privately Insured Patients Still Face Unexpected Costs for IUDs and Contraceptive Implants Under the ACA

A new analysis of insurance claims shows that privately insured patients in the U.S. are still paying out-of-pocket costs for IUD and contraceptive implant insertions—despite the Affordable Care Act’s requirement that these services be fully covered without cost-sharing. Researchers at the Kaiser Family Foundation (KFF) found that 1 in 5 privately insured women reported unexpected expenses for long-acting reversible contraception (LARC) insertion between 2021 and 2023, with median costs ranging from $20 to $150 per incident. The study, published June 16, 2024, in Contraception, examined claims data from employer-sponsored plans and identified gaps in compliance with the ACA’s contraceptive mandate.

The KFF analysis, led by Linda Li, Brittni Frederiksen, and Alina Salganicoff, highlights persistent financial barriers even after the ACA’s 2012 rule requiring insurers to cover all FDA-approved contraceptive methods without copays, deductibles, or coinsurance. "We expected to see near-zero out-of-pocket costs after the mandate took effect," said Salganicoff, a KFF senior vice president and director of women’s health policy. "Instead, we found that a significant portion of patients are still facing unexpected bills—sometimes because of misclassified codes, provider billing errors, or plan design loopholes."

Why Are Patients Still Paying for Fully Covered Contraception?

The study pinpoints three primary reasons for the cost gaps:

1. Billing Code Errors: Providers may use incorrect CPT codes (e.g., billing for a "contraceptive evaluation" instead of a "LARC insertion"), triggering patient responsibility.
2. Plan Design Flaws: Some employer-sponsored plans exclude certain brands or types of IUDs/implants from their "preferred drug list," forcing patients to pay for non-formulary devices.
3. Network Restrictions: Patients visiting out-of-network providers often face surprise bills, even when the service itself is covered.

Data from the analysis show that copayments for LARC insertions averaged $42 when misclassified as diagnostic visits, while non-formulary implant costs reached $120–$150 in some cases. The KFF team cross-referenced these findings with prior research from the Guttmacher Institute, which found that 14% of women with private insurance reported difficulty accessing contraception due to cost barriers in 2022—a figure that likely undercounts cases where patients simply absorbed unexpected fees.

How the ACA’s Contraceptive Mandate Was Supposed to Work

The ACA’s contraceptive coverage rule, finalized in 2012, explicitly states that all FDA-approved contraceptive methods—including IUDs, implants, birth control pills, and emergency contraception—must be provided without cost-sharing for patients with private insurance. Employers with 50+ workers are required to cover these services, while plans for smaller businesses or self-insured employers must comply with federal parity rules.

Yet enforcement has been inconsistent. A 2023 report from the Department of Health and Human Services (HHS) found that 1 in 3 women surveyed had encountered cost barriers to contraception in the prior year, often due to plan design exclusions or administrative hurdles. The KFF study adds granularity to this trend, showing that even when patients meet their deductible or have high-deductible plans, LARC insertions—procedures that take minutes—can still trigger unexpected fees.

What This Means for Patients and Policymakers

For patients, the takeaway is clear: always confirm with your insurer before scheduling a LARC insertion to verify that the specific device and provider are in-network and coded correctly. The KFF researchers recommend that patients:

• Ask providers to use the correct CPT codes (e.g., 58300 for IUD insertion, 58301 for implant).
• Check their plan’s formulary list for covered devices.
• File an internal appeal if billed incorrectly, citing the ACA mandate.

For policymakers, the data underscore the need for stronger oversight. HHS has previously issued guidance clarifying that insurers cannot impose cost-sharing for contraception, but compliance remains uneven. Some states—like California and New York—have passed laws requiring insurers to cover all FDA-approved methods without restrictions, but federal enforcement gaps persist.

What Comes Next: Advocacy and Potential Reforms

Advocacy groups like Planned Parenthood and the National Women’s Law Center have long pushed for federal penalties against non-compliant insurers. In 2023, the Biden administration proposed strengthening ACA enforcement by requiring insurers to report contraceptive coverage denials to HHS. However, no legislative action has been taken yet.

The KFF study does not address whether these out-of-pocket costs disproportionately affect low-income patients or women of color—a critical equity angle that prior research suggests may exist. A 2022 study in JAMA Network Open found that Black and Hispanic women were 2.5 times more likely to report cost-related barriers to contraception than white women, a disparity that could worsen if billing errors or plan design flaws remain unchecked.

Key Takeaways for Patients and Providers

• Patients: Verify coverage details before your appointment. If billed incorrectly, dispute the charge with your insurer and cite the ACA’s contraceptive mandate.
• Providers: Use precise CPT codes for LARC insertions to avoid triggering patient responsibility. Advocate for system-wide fixes, such as electronic prior-authorization alerts for non-formulary devices.
• Policymakers: Close enforcement loopholes by mandating insurer audits and public reporting on contraceptive coverage compliance.

The KFF analysis serves as a reminder that even well-established federal protections can falter at the point of care. For millions of women relying on LARCs—methods that reduce unintended pregnancy by over 99%—unexpected costs can mean the difference between consistent access and intermittent gaps in protection.